Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients.
We evaluated minimal inhibitory concentration (MIC) for vancomycin, daptomycin, and linezolid in methicillin-resistant coagulase-negative staphylococci (MR-CoNS). Minimal inhibitory concentration of 2-4 mg/l for vancomycin was observed in 16% of strains, and among them 19% had MIC at breakpoint for daptomycin or linezolid. Among strains completely susceptible to vancomycin, 16% had MIC at breakpoint for daptomycin and 11% had for linezolid. This large proportion of pathogens with MIC around the breakpoint suggests a possible risk of treatment failure with these drugs. This phenomenon is worth further and constant monitoring.
Elio
E
Castagnola
Loredana
L
Amoroso
Laura
L
Banov
Maura
M
Faraci
Anna
A
Loy
Andrea
A
Moscatelli
Francesco
F
Risso
Paola
P
Barabino
Antonella
A
Ciucci
Roberto
R
Bandettini
D000081:Acetamides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D003030:Coagulase / Q000378:metabolism; D017576:Daptomycin / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects* / Q000378:metabolism / Q000472:pathogenicity; D013329:Structure-Activity Relationship; D014640:Vancomycin / Q000097:blood / Q000302:isolation & purification / Q000494:pharmacology*
D000081:Acetamides; D000900:Anti-Bacterial Agents; D003030:Coagulase; D023303:Oxazolidinones; D014640:Vancomycin; D000069349:Linezolid; D017576:Daptomycin
Daptomycin,; Increased minimal inhibitory concentration,; Linezolid,; Methicillin-resistant coagulase-negative staphylococci,; Pediatric patients; Vancomycin,